1. FRI0137 Efficacy, safety and immunogenicity from week 30 to week 54 in a randomised, double-blind phase iii study comparing a proposed infliximab biosimilar (PF-06438179/GP1111) with reference infliximab. (12th June 2018) Authors: Alten, R.; Tseluyko, V.; Hala, T.; Mehmedagic, S.; Pileckyte, M.; Dokoupilová, E.; Jovic, D.; Rehman, M.; Zhang, M.; Sewell, L.; Hackley, S.; Salts, S.; Cronenberger, C.; Schumacher, K.; von Richter, O.; Batko, B. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 612 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. OP0248 Responder Analysis of the Effects of Abaloparatide (Parathyroid Hormone Related Peptide) and Teriparatide on Bone Mineral Density in Postmenopausal Women with Osteoporosis: Results of the Active Trial. (9th June 2015) Authors: Miller, P.D.; Hattersley, G.; Lau, E.; Alexandersen, P.; Hala, T.; Mustatea, S.; Nedergaard, B.S.; Krogsaa, A.; Slessinger, J.; Zerbini, C.; Valter, I.; Visockiene, Z.; Jendrych, B.; Kulak, C.M.; Marquez, F.; Harris, A.G.; Williams, G.C.; Hu, M.-Y.; Black, D.M.; Riis, B.J. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 165 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗